Last reviewed · How we verify
Hypertension — Treatment Landscape & Competitive Intelligence
Cardiovascular
7 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Tryvio | APROCITENTAN | Idorsia | Endothelin Receptor Antagonist [EPC] | 2025-01-01 | ||
| Candesartan Cilexetil | CILEXETIL | Alembic | Ace Inhibitor | 2021-01-01 | ||
| olmesartan medoxomil-hydrochlorothiazide | OLMESARTAN | Cosette | Thiazide Diuretic [EPC] | 2019-01-01 | ||
| Prazosin Hcl | prazosin-hcl | Pfizer | prazosin | 5-hydroxytryptamine receptor 1D | 1976-01-01 | |
| Caduet | Amlodipine Besylate | Pfizer Inc. | Dihydropyridine calcium channel blocker | L-type calcium channel | ||
| Lisinopril/HCTZ | HCTZ | Direct_Rx | Thiazide Diuretic [EPC] | |||
| Minnebro | esaxerenone | Daiichi Sankyo | Mineralocorticoid receptor |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- · 2 drugs in Hypertension
- Alembic · 1 drug in Hypertension
- Cosette · 1 drug in Hypertension
- Daiichi Sankyo · 1 drug in Hypertension
- Direct_Rx · 1 drug in Hypertension
- Idorsia · 1 drug in Hypertension
- Pfizer · 1 drug in Hypertension
- Pfizer Inc. · 1 drug in Hypertension
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Hypertension:
- Hypertension treatment updates — RSS
- Hypertension treatment updates — Atom
- Hypertension treatment updates — JSON
Cite this brief
Drug Landscape (2026). Hypertension — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/hypertension. Accessed 2026-05-13.
Related
- Hypertension full disease profile — treatment pathway, diagnostics, guidelines
- Cardiovascular area landing
- Browse all CI briefs
- Build a custom feed